We observed increased CXCR3 expression in cells from patients with AML and CMML compared with patients with MDS in the CD4 T2, CD8 T1, and CD8 T2 clusters (Fig. 1E). This evidence concerns the gene CXCR3 and chronic myelomonocytic leukemia.